Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans

Neuropsychopharmacology

Volumn 14, Issue 6, 1996, Pages 425-436

  Bonson, Katherine R ^a   Buckholtz, Joshua W ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressants; Hallucinogen; Human studies; LSD; Serotonin reuptake inhibitor

Indexed keywords

CATECHOLAMINE; FLUOXETINE; LITHIUM; LYSERGIDE; PAROXETINE; SEROTONIN; SEROTONIN 2 RECEPTOR; SERTRALINE; TRAZODONE;

ADULT; ARTICLE; CASE REPORT; CATECHOLAMINE BRAIN LEVEL; DEPRESSION; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HALLUCINATION; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SUBSTANCE ABUSE;

EID: 0030174848     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00145-4     Document Type: Article

References (98)

1. Aghajanian GK, Haigler HJ (1975): Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors. Psychopharmacol Commun 1:619-629
2. 2 agonists in rats. Pharmacol Toxicol 64:165-172
3. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW (1988): Rapid downregulation of beta-adrenoceptors by coadministration of desipramine and fluoxetine. Eur J Pharmacol 154:125-134
4. 2 serotonin receptors. Life Sci 33:2011-2016
5. Beasley CM, Masica DN, Potvin JH (1992): Fluoxetine: A review of receptor and functional effects and their clinical implications. Psychopharmacology (Berl) 107:1-10
6. Bel N, Artigas F (1993): Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245
7. Birkhimer LJ, DeVane CL, Muniz CE (1984): Mechanism and management of important psychotherapeutic drug interactions. South Med J 77:465-469
8. Blier P, de Montigny C (1983): Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3:1270-1278
9. Bonson KR, Murphy DL (1996): Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73:229-233
10. 2 receptor binding in rat brain. Eur J Pharmacol 109:421-425
11. 2 receptors. Life Sci 42:2439-2445
12. 2 receptors in rat brain. Neuropsychopharmacology 3:137-148
13. 2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide. Mol Pharmacol 42:826-830
14. 1C receptor agonist. J Pharmacol Exp Ther 258:891-896
15. Burt DR, Creese I, Snyder SH (1976): Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol Pharmacol 12:631-638
16. Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S (1992): Effects of short-and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 31:343-347
17. Callahan PM, Appel JB (1990): Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure. Psychopharmacology (Berl) 100:13-18
18. Closse A, Frick W, Dravid A, Bolliger G, Hauser D, Sauter A, Tobler HJ (1984): Classification of drugs according to receptor binding profiles. Naunyn Schmiedebergs Arch Pharmacol 327:95-101
19. Colpaert FC, Meert TF, Niemegeers CJ, Janssen PA (1985): Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 86:45-54
20. Creese I, Burt DR, Snyder SH (1975): The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 17:1715-1719
21. Cunningham KA, Appel JB (1987): Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology (Berl) 91:67-73
22. de Montigny C, Aghajanian GK (1978): Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303-1306
23. de Montigny C, Chaput Y, Blier P (1990): Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatr 51:4-8
24. 2 sites. Life Sci 32:2677-2684
25. Dytrych SGZ (1965): Blocking of LSD reaction by premedication with Niamid. Activ Nerv Super (Praha) 7:306
26. Erlander MG, Lovenberg TW, Baron BM, deLecea L, Danielson PE, Racke M, Slone AL, Siegel BW, Foye PE, Cannon K, et al (1993): Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci USA 90:3452-3456
27. Freedman DX (1969): The psychopharmacology of hallucinogenic agents. Annu Rev Med 20:409-418
28. Fuller RW (1994): Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55:163-167
29. Fuxe K, Ogren S-O, Agnati LF, Benfenati F, Fredholm B, Anderson K, Zini I, Eneroth P (1983): Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22:389-399
30. Fuxe K, Ogren SO, Agnati LF, Eneroth P, Holm AC, Andersson K (1981): Long-term treatment with zimelidine leads to a reduction in 5-hydroxytryptamine neurotransmission within the central nervous system of the mouse and rat. Neurosci Lett 21:57-62
31. Gallagher DW, Aghajanian GK (1975): Effects of chlorimipramine and lysergic acid diethylamide on efflux of precursor-formed 3-H-serotonin: Correlations with serotonergic impulse flow. J Pharmacol Exp Ther 193:785-795
32. Gardier AM, Lepoul E, Trouvin JH, Chanut E, Dessalles MC, Jacquot C (1994): Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: Relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54:PL51-56
33. 2 agonists or antagonists? Neuropsychopharmacology 3: 509-517
34. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511
35. 2 serotonin receptors: Evidence for a lack of selectivity. J Med Chem 35:734-740
36. Goff DC, Brotman AW, Waites M, McCormick S (1990): Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatr 147:492-494
37. Goldman MJ, Grinspoon L, Hunter-Jones S (1990): Ritualistic use of fluoxetine by a former substance abuser [letter]. Am J Psychiatr 147:1377
38. 2 and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J Neurochem 62:2262-2268
39. 2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol 83:235-242
40. Grof S, Dytrych Z (1965): Blocking of LSD reaction by premedication with Niamid. Act Nerv Super (Praha) 7:306
41. Gross R (1994): Abuse of fluoxetine [letter; comment]. Mayo Clin Proc 69:914
42. Heninger GR, Charney DS (1987): Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress, New York, Raven, pp 535-545
43. Hensler JG, Ordway GA, Gambarana C, Areso P, Frazer A (1991): Serotonergic neurons do not influence the regulation of beta adrenoceptors induced by either desipramine or isoproterenol. J Pharmacol Exp Ther 256: 656-664
44. Hoyer D (1989): 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In Fozard JR (ed), The Peripheral Actions of 5-Hydroxytryptamine, Oxford, Oxford University Press, pp 72-99
45. Hyttel J (1994): Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19-26
46. 2C receptor function. IUPHAR Satellite Meeting on Serotonin, Chicago, SmithKline Beecham Pharmaceuticals
47. 2 receptors in the rat brain. J Psychiatry Neurosci 19:63-67
48. Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA, van de Kar LD (1993a): Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI). J Pharmacol Exp Ther 266:836-844
49. 1A agonist, 8-OH-DPAT, in male rats. Brain Res 630:148-156
50. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11:449-458
51. 1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA 90:2184-2188
52. Lucas RA (1992): The human pharmacology of fluoxetine. Int J Obes Relat Metab Disord 16:S49-S54
53. Maj J, Moryl E (1992): Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Trans 88:143-156
54. Maj J, Moryl E (1993): Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol 3:85-94
55. Markel H, Lee A, Holmes RD, Domino EF (1994): LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 125:817-819
56. Martin-Iverson MT, Leclere JF, Fibiger HC (1983): Cholinergic-dopaminergic interactions and the mechanisms of action of antidepressants. Eur J Pharmacol 94:193-201
57. Meert TF, de Haes P, Janssen PA (1989): Risperidone (R64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology 97:206-212
58. Mittman SM, Geyer MA (1989): Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology 98: 321-329
59. Mittman SM, Geyer MA (1991): Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology 105:69-76
60. Monsma FJ, Shen Y, Ward RR, Hamblin MW, Sibley DR (1993): Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320-327
61. 3H-5-HT from rat hypothalamic slices. Naunyn Schmiedebergs Arch Pharmacol 341:398-403
62. Moret C, Briley M (1990b): Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 180: 351-356
63. Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987): Monoamine oxidase inhibitors as antidepressants: Implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress, New York, Raven, pp 545-552
64. 1A binding sites are not downregulated by agonists which induce tolerance in the rat: Myoclonus and other serotonergic behaviors. J Recept Res 12:287-197
65. 1A receptor-mediated effects of antidepressants. Prog Neuropsychopharmacol Biol Psychiatr 17:1-19
66. Nielsen EB (1985): Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J Pharmacol Exp Ther 234:244-249
67. 3H]spiroperidol binding. Behav Brain Res 16:171-176
68. Pagliaro LA, Pagliaro AM (1993): Fluoxetine abuse by an intravenous drug user. Am J Psychiatr 150:1898
69. Pato MT, Murphy DL, DeVane CL (1991): Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 11:224-225
70. 1A receptors may play a role in hallucinogenesis. J Pharmacol Exp Ther 269:1160-1165
71. Peroutka SJ, Snyder SH (1980): Long term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88-90
72. 2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide. J Pharmacol Exp Ther 247:918-925
73. Pierce PA, Peroutka SJ (1989): Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97:118-122
74. 1C cortical receptors. Naunyn Schmiedebergs Arch Pharmacol 346:4-11
75. Pieri L, Pieri M, Haefely W (1974): LSD as an agonist of dopamine receptors in the striatum. Nature 252:586-588
76. Resnick O, Krus DM, Raskin M (1964): LSD-25 Action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 3:1207-1214
77. 2 receptors: Implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98:495-499
78. 1C receptors in the choroid plexus. J Pharmacol Exp Ther 247:169-173
79. Sanders-Bush E, Burris KD, Knoth K (1988): Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928
80. Schechter LE, Bolanos FJ, Gozlan H, Lanfumey L, Haj DS, Laporte AM, Fattaccini CM, Hamon M (1990): Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: Biochemical and electrophysiological studies. J Pharmacol Exp Ther 255:1335-1347
81. 7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatment. Mol Pharmacol 47:99-103
82. Snyder SH, Peroutka SJ (1982): A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatria 15:131-134
83. Spina E, Perucca E (1994): Newer and older antidepressants: A comparative review of drug interactions. CNS Drugs 2:479-497
84. Spyraki C, Fibiger HC (1981): Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195-206
85. 3H]-siperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology 80:150-155
86. Strassman RJ (1984): Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172:577-595
87. Strassman RJ (1992): Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7:241-243
88. Tinsley JA, Olsen MW, Laroche RR, Palmen MA (1994): Fluoxetine abuse. Mayo Clin Proc 69:166-168
89. 2 receptor as a site of action for LSD and phenyLisopropylamine hallucinogens. Psychopharmacology (Berl) 94:213-216
90. Trulson ME, Crisp T (1986): Do serotonin-containing dorsal raphe neurons possess autoreceptors? Exp Brain Res 62: 579-586
91. Trulson ME, Heym J, Jacobs BL (1981): Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats. Brain Res 215:275-293
92. U.S. DHHS (1993): National Household Survey on Drug Abuse - Population Estimates of 1993, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services, DHHS Publication # (SMA)-94-3017, Washington, DC, U.S. Government Printing Office
93. Wamsley JK, Byerley WF, McCabe RT, McConnell EJ, Dawson TM, Grosser BI (1987): Receptor alterations associated with serotonergic agents: An autoradiographic analysis. J Clin Psychiatr 48:19-25
94. Westphal RS, Sanders-Bush E (1994): Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46:937-942
95. White FJ, Holohean AM, Appel JB (1983): Antagonism of a behavioral effect of LSD and lisuride in the cat. Psychopharmacology (Berl) 80:83-84
96. Wilcox JA (1987): Abuse of fluoxetine by a patient with anorexia nervosa [letter]. Am J Psychiatr 144:1100
97. Willner P (1989): Sensitization to the actions of antidepressant drugs. In Goudie AJ, Emmett-Oglesby MW (eds), Psychoactive Drugs: Tolerance and Sensitization, Clifton, NJ, Humana Press, pp 407-459
98. Winter JC, Rabin RA (1988): Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav 30:617-624